ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO2531

Finerenone and Kidney Outcomes in Patients with CKD and T2D: Results from FIDELITY

Session Information

Category: Diabetic Kidney Disease

  • 602 Diabetic Kidney Disease: Clinical


  • Bakris, George L., University of Chicago Medicine Infectious Diseases & Global Health, Chicago, Illinois, United States
  • Ruilope, Luis M., Instituto de Investigacion en Ciencias de la Salud, Madrid, Spain
  • Anker, Stefan D., Charite Universitatsmedizin Berlin - Campus Virchow-Klinikum, Berlin, Berlin, Germany
  • Filippatos, Gerasimos, Ethniko kai Kapodistriako Panepistemio Athenon Iatrike Schole, Athens, Attica, Greece
  • Pitt, Bertram, University of Michigan Medical School, Ann Arbor, Michigan, United States
  • Rossing, Peter, Steno Diabetes Center Copenhagen, Gentofte, Denmark
  • Fried, Linda F., University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States
  • Roy-Chaudhury, Prabir, University of North Carolina School of Medicine Neuroscience Center, Chapel Hill, North Carolina, United States
  • Sarafidis, Pantelis, Aristoteleio Panepistemio Thessalonikes, Thessaloniki, Central Macedonia, Greece
  • Ahlers, Christiane, Bayer AG, Wuppertal, Nordrhein-Westfalen, Germany
  • Joseph, Amer, Bayer AG, Wuppertal, Nordrhein-Westfalen, Germany
  • Brinker, Meike Daniela, Bayer AG, Wuppertal, Nordrhein-Westfalen, Germany
  • Lawatscheck, Robert, Bayer AG, Berlin, Berlin, Germany
  • Agarwal, Rajiv, Indiana University School of Medicine, Indianapolis, Indiana, United States

FIDELITY, a prespecified meta-analysis of FIDELIO-DKD and FIGARO-DKD, evaluates the efficacy and safety of finerenone across a spectrum of patients with chronic kidney disease (CKD) and type 2 diabetes (T2D).


FIDELITY combines individual patient data from FIDELIO-DKD (NCT02540993) and FIGARO-DKD (NCT02545049). Eligible patients were adults with T2D and CKD (urine albumin-to-creatinine ratio [UACR] ≥30–<300 mg/g and estimated glomerular filtration rate [eGFR] ≥25–≤90 mL/min/1.73 m2, or UACR ≥300–≤5000 mg/g and eGFR ≥25 mL/min/1.73 m2), treated with optimized renin–angiotensin system blockade. Efficacy outcomes included a composite kidney outcome of time to first onset of kidney failure (end-stage kidney disease [ESKD] or sustained eGFR <15 mL/min/1.73 m2), sustained ≥57% decrease in eGFR from baseline over ≥4 weeks, or renal death.


In 13,026 patients, over 3.0 years’ median follow-up, finerenone reduced the risk of the kidney composite outcome by 23% vs placebo (HR=0.77; 95% CI 0.67–0.88; P=0.0002); consistent benefits were observed across baseline eGFR and UACR subgroups (Pinteraction 0.62 and 0.67, respectively). Compared with placebo, finerenone led to a nominally significant reduction in the incidence of all nonfatal components of the kidney composite outcome, including a 20% lower risk of ESKD (chronic dialysis or kidney transplant; HR=0.80; 95% CI 0.64–0.99; P=0.04). Finerenone caused an initial drop in eGFR vs placebo (least-squares [LS] mean change in eGFR slope from baseline to month 4, –3.3 vs –1.0 mL/min/1.73 m2) but slowed long-term eGFR decline (LS mean change in eGFR slope from month 4 onwards, –2.5 vs –3.7 mL/min/1.73 m2/year). The incidence of adverse events was similar between groups. The incidence of permanent discontinuation due to hyperkalemia in finerenone and placebo recipients with an eGFR <60 mL/min/1.73 m2 was 2.4% and 0.8%, respectively, and 0.6% and 0.3% in those with an eGFR ≥60 mL/min/1.73 m2.


FIDELITY demonstrates robust kidney benefits and safety of finerenone in patients with T2D across the spectrum of CKD severity.


  • Commercial Support